United States-based pharmaceutical and biotechnology corporation Pfizer announced on Thursday that it has named Elif Aral as its new regional president for Middle East, Russia and Africa (MERA), effective September 2024.
In the new role, Aral is to spearhead operations in the region and bring scientific breakthroughs in vaccines, oncology, rare diseases, internal medicine, hospitals and inflammation and immunology. She will also drive strategic initiatives aimed at improving healthcare access and equity, working closely with regional partners and governments to ensure the company's leading portfolio and breakthroughs reach those who need them. This is in addition to managing all therapeutic areas within the MERA region.
Aral began her career with Pfizer in 1995 and most recently led the company's 'An Accord for a Healthier World' initiative. She has served as the CV Metabolic and Global Brands Lead in Internal Medicine and also as the Vaccines Lead for Emerging Markets.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Sanofi in talks to sell Opella stake
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
MedImmune's FluMist nasal spray influenza vaccine receives US FDA approval
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults